Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

Among them, WW International (WW), formerly known as WeightWatchers, hit a rough patch earlier this year, resulting in WW ...

Digging Into the Bargain Bin Investing in beaten-down stocks can be a savvy strategy for long-term wealth creation, as it ...

HDFC Securities downgrades Eris to Add from Buy, as the strong run-up in the stock price factors in near-term triggers.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

A once-weekly injection of Wegovy® has become available in Singapore, marking the latest step in managing obesity as a ...

The global geriatric care services market, valued at $1 trillion in 2022, is projected to more than double by 2033, driven by ...

The ASX fell 0.11pc in trade, with 7 of 11 sectors lower. The resources industry was a silver lining; both gold and iron ore ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...